AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20491143
Drug: Conservative (restrictive)
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative (restrictive) infusion strategy
Trial: 20491143
Drug: Liberal (traditional)
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal (traditional) infusion strategy
Trial: 14662708
Drug: ADMA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADMA infusion at a dose of 0.25 mg ADMA x kg(‐1) x min(‐1)
Trial: 14662708
Drug: N(G)-nitro-L-arginine methyl
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-nitro-L-arginine methyl ester infusion at a dose of 3 microg x kg(‐1) x min(‐1)
Trial: 11703963
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with low-fat foods enriched with 1.25 to 5.0 g/day of nonesterified plant sterols and mineral nutrients (calcium, magnesium, potassium)
Trial: 23092785
Drug: Rifaximin plus
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin plus fibre supplementation (400 mg b.d. for one week per month + 3.5 g high-fibre supplementation b.d.)
Trial: 23092785
Drug: Fibre supplementation
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplementation alone (3.5 g high-fibre supplementation b.d.)
Trial: 20525840
Drug: Combination glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination glucosamine and chondroitin sulphate
Trial: 20525840
Drug: Chondroitin sulphate
RxNorm normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulphate 400 mg three times daily
Trial: 10519500
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (250 microg/kg bolus followed by 13 microg x kg(‐1) x h(‐1) infusion)
Trial: 10519500
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (equivalent volume to lidocaine)
Trial: 7492104
Drug: A77003 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A77003 at 0.035 mg/kg/h
Trial: 7492104
Drug: A77003 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A77003 at 0.07 mg/kg/h
Trial: 7492104
Drug: A77003 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A77003 at 0.14 mg/kg/h
Trial: 7492104
Drug: A77003 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A77003 at 0.28 mg/kg/h
Trial: 6182516
Drug: Oral combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combined preparation (antihistamine + decongestant)
Trial: 31407802
Drug: 0.5% G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% G. speciosum ethanolic extract (GSE) serum applied for 56 days
Trial: 25085517
Drug: CMT Neuropathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT Neuropathy Score (CMTNS) components including Ulnar compound motor action potential (CMAP), leg motor symptoms, arm motor symptoms, leg strength, and sensory symptoms
Trial: 6742743
Drug: Midazolam alone
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam alone or in combination with pentazocine
Trial: 31204771
Drug: ∼3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ∼3 g/d DHA
Trial: 31204771
Drug: ∼3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ∼3 g/d EPA
Trial: 27055965
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg/d)
Trial: 27055965
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sesame oil blend and nifedipine (20 mg/d)
Trial: 25194085
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for 15 days
Trial: 25194085
Drug: Phytotherapeutic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapeutic agents for 30 days plus 15 days antibiotic treatment
Trial: 25194085
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Antibiotic treatment only for 15 days)
Trial: 18043478
Drug: darunavir/ritonavir (400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir (400/100 mg) twice a day
Trial: 18043478
Drug: saquinavir/ritonavir (1000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ritonavir (1000/100 mg) twice a day
Trial: 18043478
Drug: darunavir/saquinavir/ritonavir (400/1000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/saquinavir/ritonavir (400/1000/100 mg) twice a day
Trial: 16107961
Drug: Undiluted Lancy-Vaxina
RxNorm normalized name: Fancy Falsegoldenaster Flower
DrugBank: Heterotheca inuloides flower (DB14331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiluted Lancy-Vaxina vaccine (n=56)
Trial: 16107961
Drug: Diluted Lancy-Vaxina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted Lancy-Vaxina vaccine (n=56)
Trial: 2305610
Drug: Glucose-free 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-free 2% lidocaine (80 mg)
Trial: 2305610
Drug: Hyperbaric 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 5% lidocaine (80 mg)
Trial: 7386343
Drug: 167 mg
RxNorm normalized name: silymarin 167 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 167 mg of citrated caffeine
Trial: 7386343
Drug: 324 mg
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 324 mg of citrated caffeine
Trial: 7386343
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of citrated caffeine
Trial: 7386343
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg of caffeine)
Trial: 31551249
Drug: HDV-insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HDV-insulin lispro (HDV-L)
Trial: 19393928
Drug: Intra-articular shoulder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular shoulder injections using steroid with distension
Trial: 16675705
Drug: Serogroup C
RxNorm normalized name: Neisseria meningitidis serogroup C Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup C glycoconjugate vaccine
Trial: 12934956
Drug: Real millimeter
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real millimeter wave therapy (MWT) sessions, n=4
Trial: 10928302
Drug: Long-acting calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting calcium channel blockers
Trial: 8623869
Drug: Antibiotics effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics effective against group B streptococci
Trial: 1549403
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b Neisseria meningitidis outer membrane protein conjugate vaccine (PedvaxHIB)
Trial: 4001836
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of porcine GIP at a dose of 1.0 microgram . kg‐1 . h‐1
Trial: 29979421
Drug: Preoperative injection
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative injection of carbon nanoparticles (CNs)
Trial: 29979421
Drug: Intraoperative injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of carbon nanoparticles (CNs)
Trial: 26890267
Drug: Intravenous preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous preemptive analgesia (IV-PCA) with fentanyl started before skin incision
Trial: 24528331
Drug: warfarin transitioned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin transitioned to rivaroxaban 20 mg once daily (group A)
Trial: 24528331
Drug: warfarin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin followed by placebo once daily (group B)
Trial: 24528331
Drug: rivaroxaban alone
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rivaroxaban alone 20 mg once daily (group C)
Trial: 22222996
Drug: LipiFlow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow treatment (12 minutes)
Trial: 22222996
Drug: iHeat Warm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iHeat Warm Compress (5 minutes daily for 2 weeks)
Trial: 22222996
Drug: LipiFlow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow treatment (12 minutes) in crossover group
Trial: 12198044
Drug: Sufentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil target concentration (STC) 0.1 ng/mL
Trial: 12198044
Drug: Sufentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil target concentration (STC) 0.2 ng/mL
Trial: 12198044
Drug: Sufentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil target concentration (STC) 0.3 ng/mL
Trial: 12198044
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration 5.0 microg/mL
Trial: 12198044
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration 4.0 microg/mL
Trial: 12198044
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration 2.5 microg/mL
Trial: 11575576
Drug: Low group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low group (160 g of tomato juice plus 320 g of control drink)
Trial: 11575576
Drug: High group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High group (480 g of tomato juice)
Trial: 11575576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (480 g of control drink)
Trial: 8141442
Drug: Fentanyl/midazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl/midazolam (1 mg/25 mg; dosage 0.1 ml/kg/h)
Trial: 8141442
Drug: Ketamine/midazolam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine/midazolam (250 mg/25 mg; dosage 0.1 ml/kg/h)
Trial: 2900980
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (n = 53) - second-look laparotomy followed by cyclical oral chlorambucil
Trial: 2900980
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (n = 57) - oral chlorambucil without second-look operation
Trial: 18465343
Drug: Oral pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate (150 mg twice daily for 4 years)
Trial: 16540947
Drug: 4INJ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4INJ group (n = 42) receiving four injections of methylprednisolone sodium succinate
Trial: 16540947
Drug: 1INJ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1INJ group (n = 42) receiving one injection of methylprednisolone followed by three injections of normal saline
Trial: 16540947
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 43) receiving four injections of normal saline
Trial: 10630947
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection of 1.8 mL of 3% mepivacaine
Trial: 10630947
Drug: Mock intraosseous
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock intraosseous injection
Trial: 1391258
Drug: Chlorothiazide (diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (diuretic therapy)
Trial: 16762982
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone once daily for 4 weeks
Trial: 16762982
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of TNF-alpha (10 ng/100 mL forearm volume/min for 2 h)
Trial: 2892254
Drug: Nizatidine 30
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 30 mg
Trial: 2892254
Drug: Nizatidine 100
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine 100 mg
Trial: 13678868
Drug: Candesartan (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (titrated to 32 mg once daily)
Trial: 10543583
Drug: Megadose Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megadose Vitamin C (1000 mg hourly for the first 6 hours, then 3 times daily thereafter)
Trial: 10543583
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pain relievers and decongestants)
Trial: 2070311
Drug: Split-virion vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-virion vaccine (SVV)
Trial: 2070311
Drug: Whole-virion vaccine
RxNorm normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virion vaccine (WVV)
Trial: 31524141
Drug: US-guided injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided injection (n=23)
Trial: 31524141
Drug: Blind injection
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injection (n=24)
Trial: 28853992
Drug: Control cookies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cookies (CC)
Trial: 26376447
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg, single dose)
Trial: 23711703
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapy (ACT) AS+SP
Trial: 23711703
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapy (ACT) AM+LF
Trial: 12872150
Drug: IFN-α (IFN)
RxNorm normalized name: IFNγ
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α (IFN) treatment
Trial: 12872150
Drug: No IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IFN treatment (Control)
Trial: 11091498
Drug: G-CSF (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (arm A)
Trial: 11091498
Drug: GM-CSF/G-CSF (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF/G-CSF (arm C)
Trial: 9350159
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone (IMD)
Trial: 9350159
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (OP)
Trial: 31865628
Drug: Cannabis (300-μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (300-μg/kg delta-9-tetrahydrocannabinol)
Trial: 30220290
Drug: Multisymptom tablet
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisymptom tablet (containing paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate)
Trial: 30220290
Drug: Multisymptom tablet
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisymptom tablet
Trial: 27941973
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide (125-250mg/bid) plus hypertonic saline solution (HSS)
Trial: 24888857
Drug: MBP+oral antibiotics
RxNorm normalized name: MBP-091
DrugBank: MBP-091 (DB17741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP+oral antibiotics
Trial: 24888857
Drug: Overall evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall evidence-based preparation
Trial: 22226313
Drug: Homeopathic medicines
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medicines
Trial: 20307657
Drug: Microdose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose (100 microg) of (14)C-drug administered orally
Trial: 20307657
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose (120mg) of fexofenadine administered orally
Trial: 20307657
Drug: Microdose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose (100 microg) of (14)C-drug administered intravenously
Trial: 20307657
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose (120mg) of fexofenadine administered with intravenous tracer dose (100 microg) of (14)C-drug
Trial: 15816442
Drug: Total mesorectal
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total mesorectal excision (TME) with adjuvant systemic chemotherapy and radiotherapy
Trial: 15816442
Drug: Total mesorectal
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total mesorectal excision (TME) with adjuvant stop-flow perfusion along with systemic chemotherapy
Trial: 7044387
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of pirenzepine
Trial: 7044387
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of pirenzepine
Trial: 25847941
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) chemotherapy (n = 41)
Trial: 25847941
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) chemotherapy (n = 11 with gpNMB overexpression)
Trial: 25847941
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) chemotherapy (n = 11 with TNBC)
Trial: 25847941
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) chemotherapy (n = 6 with gpNMB-overexpressing TNBC)
Trial: 24905305
Drug: Vitamin-E along
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin-E along with regular medicines
Trial: 24905305
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (pregabalin with oral hypoglycemic agents)
Trial: 22822075
Drug: Calcium acetate,
RxNorm normalized name: Calcium Acetate, 667 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium acetate, lanthanum carbonate, sevelamer carbonate (active therapy)
Trial: 18198804
Drug: Standard interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interventions (mask optimization, heated humidification, topical nasal therapy, sleep apnea education)
Trial: 16310576
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (30 grams daily for 12 weeks)
Trial: 9829029
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy (BT) plus fluvoxamine (maximum dosage 300 mg, mean dose 288.1 mg)
Trial: 9829029
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy (BT) plus placebo
Trial: 31285228
Drug: Filociclovir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filociclovir (100 mg, 350 mg, or 750 mg daily for 7 days)
Trial: 31285228
Drug: Filociclovir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filociclovir (750 mg)
Trial: 31285228
Drug: Filociclovir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filociclovir (100 mg, 350 mg, or 750 mg)
Trial: 31285228
Drug: Filociclovir (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filociclovir (350 mg)
Trial: 28138867
Drug: Relational active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relational active music therapy treatments
Trial: 28138867
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (physiotherapy and occupational therapy) + Relational active music therapy